The study, which is being conducted at multiple sites across Southern Ontario, will evaluate the safety and pharmacokinetics of single ascending doses of TTI-1612 in IC/BPS patients.
TTI-1612 is a recombinant growth factor that is administered directly into the bladder.
It is being developed to correct the dysfunction and restore the bladder epithelium to a normal, healthy state.
Trillium drug development director Penka Petrova said the company is looking forward to expanding the program into the US and beyond with the start of its next trial in 2013.